Showing 14441 companies
Company Headquarters: Dubai, UAE Founded: 1954 Workforce: ~4,600 Company Working: Meda Pharmaceuticals operates as a subsidiary of Mylan NV and is actively involved in the production, distribution, and marketing of prescription and OTC pharmaceutical products. The company operates through the following business segments— allergy, pain management, gastrointestinal, urology, cardio and CNS, dermatology, and OTC. It has a direct presence in 60 countries and it also offers its products through distributors in more than 150 countries including Australia, China, Italy, South Africa, the UK, and the UAE. More than 50% of its revenue comes from respiratory, dermatology, and pain and inflammation therapeutic areas
Company Headquarters: Japan Founded: 1925 Workforce: ~ 47,347 Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
| Metric | FY2023 | FY2024 | FY2025 | |---|---|---|---| | Employees (approx., company boilerplate) | — | 9000 | 9000 | Note: UCB communicates headcount as "approximately 9,000" (2024) and "more than 9,000" (2025). UCB is a Brussels-headquartered, family-anchored global biopharmaceutical company focused exclusively on severe diseases of the immune system and the central nervous system. Over two decades it has transformed from a diversified chemicals-and-pharma conglomerate into a pure-play specialty biopharma, and over the past three years from a CNS/epilepsy-led franchise into an immunology-led growth company. Its flagship, BIMZELX (bimekizumab), the first and only approved dual IL-17A/IL-17F inhibitor, became UCB's largest product in 2025 (€2.23bn net sales) and carries a company peak-sales ambition of at least €7bn, with protection to 2037. Alongside BIMZELX, four further "growth drivers" — FINTEPLA, RYSTIGGO, ZILBRYSQ and EVENITY — generated more than €3.3bn combined in 2025. With 2025 revenue of €7.74bn (+26%), adjusted EBITDA of €2.64bn and no major loss of exclusivity until 2033, UCB is one of Europe's fastest-growing mid-cap pharmaceutical companies, now layering next-generation modalities (T-cell engagers, cell therapy) through acquisitions. --- ### Company's own description In its FY2025 and HY2026 disclosures, UCB describes itself as a global biopharmaceutical company focused on discovering and developing innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or the central nervous system. The IAR 2025 (Note 1) characterises the group as focused on severe diseases in two main therapeutic areas, neurology and immunology, and confirms that the group operates as a single reportable segment, "Biopharmaceuticals" (IAR 2025, Note 3.5), with the Executive Committee as chief operating decision maker. ### Independent characterisation UCB is a vertically integrated, research-based specialty biopharma that: 1. **Discovers** antibodies and other modalities in-house (with a heritage in antibody engineering from Celltech, acquired 2004) and increasingly in-licenses or acquires novel modalities (bispecific/multispecific T-cell engagers from Antengene and Candid; regenerative neural cell therapy from Neurona). 2. **Develops** through global Phase 1–4 programmes, with a late-stage Phase 3 success rate the company cited at 86% in mid-2025 (UCB IR blog, 31 Jul 2025). 3. **Manufactures** biologics and small molecules in an owned network in Belgium (Braine-l'Alleud bioplant and gene therapy facility), Switzerland and elsewhere, supplemented by U.S. contract manufacturers, with a new U.S. biologics campus under development in Georgia. 4. **Commercialises** directly in ~40 countries, with the United States now its dominant market (63% of 2025 net sales before hedging), and through partners in selected geographies (Amgen/Astellas for EVENITY; Nippon Shinyaku for FINTEPLA in Japan; Biogen co-development for dapirolizumab pegol). ### Business model and revenue model | Revenue stream (FY2025) | € million | % of revenue | Nature | |---|---|---|---| | Net sales (products) | 7388 | 95.4 | Product revenue net of rebates, chargebacks, Medicaid/Medicare deductions | | Royalty income and fees | 88 | 1.1 | Licensing of antibody IP ("Biotechnology IP" €54m) and other royalties (€34m) | | Other revenue | 265 | 3.4 | Contract manufacturing for buyers of divested brands (€184m) plus R&D partner payments and milestones (€81m) | | Total revenue | 7741 | 100.0 | — | UCB's revenue model is overwhelmingly product sales of prescription medicines sold to wholesalers, specialty pharmacies, hospitals and government/payer channels. Supplementary revenue streams are: Source: IAR 2025, sections 1.5–1.6. A distinctive feature is that the EVENITY (romosozumab) collaboration with Amgen is mostly not captured in revenue: UCB books only European net sales (€137m in 2025), while its share of worldwide net earnings outside Europe is booked in "other operating income" (€632m in 2025, €379m in H1 2026). This makes EVENITY a far larger profit contributor than its revenue line suggests. There is no subscription or service revenue of note; digital/patient-support services (e.g., UCBCares) are cost centres supporting product sales. ### Value chain position UCB sits at the originator end of the pharmaceutical value chain: target discovery → molecule engineering → clinical development → regulatory → manufacturing → commercialisation. It is a price-setter for patented specialty products but a price-taker vis-à-vis U.S. pharmacy benefit managers (PBMs), Medicaid and European HTA/reimbursement bodies. Gross-to-net management is a core competency, as illustrated by the H1 2026 favourable gross-to-net accrual adjustment and the H2 2026 net price pressure flagged for BIMZELX after a major PBM moved it to first-line coverage effective 1 June 2026 (HY2026 call, as summarised by GuruFocus). ### Customer types and end-markets | Customer / payer type | Relevance | |---|---| | Specialist physicians (dermatologists, rheumatologists, neurologists, epileptologists, neuromuscular specialists, osteoporosis specialists) | Prescribers for all core products | | U.S. specialty pharmacies, wholesalers, PBMs, commercial insurers | Largest channel; U.S. = €4.61bn net sales in 2025 | | U.S. government programmes (Medicaid, Medicare) | Material — Jefferies (Oct 2025) estimated Medicaid at ~27% of the BIMZELX patient base vs ~10% industry average (third-party estimate) | | European national/regional health systems and hospitals | €1.76bn net sales in 2025 | | Japanese health system (NHI price list) | €315m net sales in 2025 | | International markets (Canada, LatAm, APAC ex-Japan, Turkey, etc.) | €612m net sales in 2025 | | Pharma partners and acquirers of divested brands | Contract manufacturing and royalties | **End-markets served:** immuno-dermatology (psoriasis, hidradenitis suppurativa), rheumatology (psoriatic arthritis, axial spondyloarthritis, rheumatoid arthritis), gastroenterology (Crohn's disease, U.S. only for CIMZIA), epilepsy and rare epileptic syndromes (Dravet, Lennox-Gastaut, CDKL5 deficiency disorder), generalised myasthenia gravis, rare mitochondrial disease (TK2 deficiency), postmenopausal osteoporosis (EVENITY, Europe), Parkinson's disease and restless legs (NEUPRO), and allergy (ZYRTEC/XYZAL, established brands).
Unlock Verified Contacts
Access verified employee contacts
Decision-maker information to support your sales, lead generation, and business development. 5 users, 5,500 credits a month with rollover, and one credit per contact email.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence